aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-ã agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.
Company profile
Ticker
ALGS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aligos Belgium BV • Aligos Australia Pty LTD • Aligos Therapeutics (Shanghai) Co. Ltd. ...
ALGS stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
16 Apr 24
S-8
Registration of securities for employees
12 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
12 Mar 24
8-K
Departure of Directors or Certain Officers
28 Feb 24
SC TO-I/A
Issuer tender offer statement (amended)
28 Feb 24
SC TO-I
Issuer tender offer statement
30 Jan 24
SC TO-C
Information about tender offer
25 Jan 24
8-K
Other Events
25 Jan 24
424B3
Prospectus supplement
28 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 70.50 mm | 70.50 mm | 70.50 mm | 70.50 mm | 70.50 mm | 70.50 mm |
Cash burn (monthly) | 6.79 mm | 1.33 mm | 6.36 mm | 7.07 mm | 6.78 mm | 6.09 mm |
Cash used (since last report) | 45.37 mm | 8.92 mm | 42.48 mm | 47.23 mm | 45.30 mm | 40.72 mm |
Cash remaining | 25.13 mm | 61.58 mm | 28.02 mm | 23.27 mm | 25.20 mm | 29.78 mm |
Runway (months of cash) | 3.7 | 46.1 | 4.4 | 3.3 | 3.7 | 4.9 |
Institutional ownership, Q3 2023
50.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 41 |
Opened positions | 3 |
Closed positions | 7 |
Increased positions | 3 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 18.74 bn |
Total shares | 37.85 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
EcoR1 Capital | 3.95 mm | $2.95 bn |
Vivo Capital VIII | 3.55 mm | $46.82 mm |
Vivo Capital | 3.55 mm | $2.65 bn |
Tang Capital Management | 3.33 mm | $2.49 bn |
Roche Finance | 3.09 mm | $85.50 mm |
Tang Capital Partners | 2.82 mm | $0.00 |
Versant Venture Management | 2.32 mm | $1.73 bn |
Hillhouse Capital Advisors | 2.31 mm | $1.73 bn |
Baker Bros. Advisors | 2.08 mm | $1.55 bn |
Versant Venture Capital VI | 1.46 mm | $48.99 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Matthew W. McClure | Stock Option Common Stock | Grant | Acquire A | No | No | 1.13 | 72,000 | 81.36 k | 72,000 |
1 Mar 24 | Lesley Ann Calhoun | Stock Option Common Stock | Grant | Acquire A | No | No | 1.13 | 308,940 | 349.10 k | 308,940 |
1 Mar 24 | Julian A. Symons | Stock Option Common Stock | Grant | Acquire A | No | No | 1.13 | 72,000 | 81.36 k | 72,000 |
1 Mar 24 | Lawrence Blatt | Stock Option Common Stock | Grant | Acquire A | No | No | 1.13 | 965,435 | 1.09 mm | 965,435 |
28 Feb 24 | Peter Hirth | Stock Option Common Stock | Grant | Acquire A | No | No | 0.96 | 4,411 | 4.23 k | 4,411 |
27 Feb 24 | Peter Hirth | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 26.58 | 15,000 | 398.70 k | 0 |
News
Earlier Announced, Aligos Therapeutics Has Been Awarded A $1.3M NIH Contract To Conduct Clinical Development Of A Compound For The Treatment Of Covid-19
1 Apr 24
Aligos Therapeutics Presents Clinical Data At APASL 2024 From ALG-055009 And ALG-000184 Phase 1 Studies
27 Mar 24
12 Health Care Stocks Moving In Friday's After-Market Session
15 Mar 24
Recap: Aligos Therapeutics Q4 Earnings
12 Mar 24
Aligos Therapeutics Q4 2023 GAAP EPS $(0.22) Beats $(0.27) Estimate, Sales $2.009M Beat $1.600M Estimate
12 Mar 24
Press releases
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
3 Apr 24
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
27 Mar 24
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
5 Mar 24